Contineum Therapeutics (NASDAQ:CTNM) Coverage Initiated by Analysts at Royal Bank of Canada

Investment analysts at Royal Bank of Canada started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $30.00 price target on the stock. Royal Bank of Canada’s target price suggests a potential upside of 94.17% from the company’s previous close.

CTNM has been the subject of several other research reports. Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $29.00 target price for the company. Morgan Stanley assumed coverage on shares of Contineum Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $25.00 price target for the company.

Contineum Therapeutics Trading Down 1.0 %

CTNM stock opened at $15.45 on Tuesday. Contineum Therapeutics has a one year low of $13.90 and a one year high of $16.06.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).